A group of researchers aimed to compare the incidence and outcomes of IE after TAVR using a supra?annular, self?expanding platform (CoreValve and Evolut) to SAVR.

Three randomised clinical trials comparing TAVR to SAVR, as well as a prospective continuous TAVR access research, were pooled for their analysis. The modified Duke criteria was used to define IE. A total of 2249 patients were included in their study.

The cumulative incidence of IE was calculated using a cause-specific hazard model. The Kaplan–Meier method was used to determine all-cause mortality estimates. The valve implant cohort's outcomes were presented.

 12 (0.5%) of 2249 patients underwent TAVR, and 21 (1.1%) of 1828 patients underwent SAVR had IE over a mean follow-up time of 2.171.51 years. Diabetes mellitus was more common in patients with IE than in those without (57.6% versus 34.2 %; P=0.005).

At one year, the rate of all-cause death in patients with IE was 27.3% (95 % CI, 1.0 %–53.6 %) in the TAVR group and 51.8 % (95 % CI, 28.2 % –75.3 %) in the SAVR group (logrank P=0.15).

After 5 years, the cumulative incidence of IE following TAVR was 1.01 % (95% CI, 0.47 % –1.96 %) and 1.58 % (95 % CI, 0.97 % –2.46 %) (P=0.047).


The study's authors concluded that TAVR with a supra-annular, self-expanding device was found to have a low cumulative incidence of IE regardless of treatment mode, although its risk was lower in the TAVR implant group. Once IE occurred, the death rate was increased.


TAVR,infective endocarditis,transcatheter therapy,interventional cardiology




Disease Condition ,Therapeutic Modality ,Myocardial Disease and Cardiomyopathies,Interventional Cardiology,DCMP_others,Trans catheter Therapy ,TINC_others